Depression is a common mental disorder that affects people of all ages across the world. All current pharmacological interventions are based on the monoamine theory of depression and aim to increase the concentrations of monoamines in the brain. However, since many patients show no response or do not tolerate conventional therapies, there is an urgent need to identify new therapeutic targets, explore new molecular pathways and develop novel drugs against depression. Opioids, a class of compounds used against chronic pain, have major analgesic properties, but they are also well known for their anxiolytic and antidepressant effects. In preclinical and clinical studies, some opioids showed encouraging results to alleviate depressionlike symptoms. Although our knowledge about the antidepressant effects of opioids stretches back to the late "70s, we still have a long way to cover. Predominantly, a clear understanding about their mode of action as well as the opioid-associated issues of addiction and convulsions, are the main challenges that need to be addressed before we will see opioid compound used in the clinic against depression. 
Although today, there is still a "chicken & egg" type of discussion regarding the causal relationship between pain, anxiety and depression, a significant clinical association between these three conditions is widely accepted (Figure 1 ). Their pharmacological treatments have attracted particular attention since they share common efficacies; effective anxiolytics show efficacy against depression and chronic pain, and vice versa [37] [38] [39] . Nevertheless, the use of clinically used opioids for the treatment of anxiety and depression in particular, has not been explored sufficiently, although the euphoric effects of opioids have been described since the late "70s 40 .
3 Opioids as antidepressants: how close are we?
The antidepressant effects of opioids have been explored extensively during the last few decades as shown in Table 2 , clinical studies on DOP agonists are also rare. In addition, the pharmacological trend of turning away from peptidic opioids towards non-peptidic analogues, brought the limitations of manifested convulsions for some DOP receptor agonists to the surface, although these could be prevented by a slow doseescalation strategy 57, 58 . Overall, the unexplored molecular 
